| Hieu T Campus, MD | |
|
655 Harmon Loop Road, Ste. 108, Dededo, GU 96929-9692 | |
| (671) 633-4447 | |
| (671) 633-4452 |
| Full Name | Hieu T Campus |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 655 Harmon Loop Road, Dededo, Guam |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689629362 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blue Ocean Medical Group Llc | 1153651112 | 4 |
News Archive
Among thousands of hospital patients treated for a "mini stroke," those who were at highest risk for suffering a full-blown ischemic attack were less likely to received optimal care, according to a study led by researchers at Duke Medicine.
Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today Damian Marron, CEO, TxCell will be presenting at the 13th Annual BIO Investor Forum, October 7-8, 2014 at the Palace Hotel in San Francisco, California, US.
Buffalo (N.Y.) News: "Two of the region's three dominant health insurers intend to raise premiums on average by double digits for next year, and the third wants a double-digit increase for plans not structured as health maintenance organizations. The premium for one insurance plan could rise almost 36 percent. The insurers cite rising costs of medical care and federal health care reforms." The increases must be approved by the state (Epstein, 10/10).
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. The study is published today in the online edition of the journal Blood.
› Verified 9 days ago
| Entity Name | Blue Ocean Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235791203 PECOS PAC ID: 1153651112 Enrollment ID: O20190918001926 |
News Archive
Among thousands of hospital patients treated for a "mini stroke," those who were at highest risk for suffering a full-blown ischemic attack were less likely to received optimal care, according to a study led by researchers at Duke Medicine.
Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today Damian Marron, CEO, TxCell will be presenting at the 13th Annual BIO Investor Forum, October 7-8, 2014 at the Palace Hotel in San Francisco, California, US.
Buffalo (N.Y.) News: "Two of the region's three dominant health insurers intend to raise premiums on average by double digits for next year, and the third wants a double-digit increase for plans not structured as health maintenance organizations. The premium for one insurance plan could rise almost 36 percent. The insurers cite rising costs of medical care and federal health care reforms." The increases must be approved by the state (Epstein, 10/10).
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. The study is published today in the online edition of the journal Blood.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hieu T Campus, MD 655 Harmon Loop Rd, Ste 108, Dededo, GU 96929-6544 Ph: (206) 660-3955 | Hieu T Campus, MD 655 Harmon Loop Road, Ste. 108, Dededo, GU 96929-9692 Ph: (671) 633-4447 |
News Archive
Among thousands of hospital patients treated for a "mini stroke," those who were at highest risk for suffering a full-blown ischemic attack were less likely to received optimal care, according to a study led by researchers at Duke Medicine.
Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today Damian Marron, CEO, TxCell will be presenting at the 13th Annual BIO Investor Forum, October 7-8, 2014 at the Palace Hotel in San Francisco, California, US.
Buffalo (N.Y.) News: "Two of the region's three dominant health insurers intend to raise premiums on average by double digits for next year, and the third wants a double-digit increase for plans not structured as health maintenance organizations. The premium for one insurance plan could rise almost 36 percent. The insurers cite rising costs of medical care and federal health care reforms." The increases must be approved by the state (Epstein, 10/10).
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. The study is published today in the online edition of the journal Blood.
› Verified 9 days ago
Dr. Maria Chela Arana Mariano, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 330 W Marine Corps Dr, Dededo, GU 96929 Phone: 671-637-8112 Fax: 671-637-8113 | |
Dawn Dee Ostberg, FNP-BC Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4404 Fax: 671-633-4452 | |
Dr. Edna Ganacias-acuna, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Route 3, Dededo, GU 96929 Phone: 671-645-5500 Fax: 671-645-5549 | |
Luis G Cruz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4447 Fax: 671-633-4452 | |
Delores Johanne Lee, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4447 | |
Dr. Arania Oceanis Adolphson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 108, Dededo, GU 96929 Phone: 671-633-4447 |